DDInter219 DDInter298
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Bleomycin {u} (Compound) treats {v} (Disease) testicular cancer
testicular cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bleomycin {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Bleomycin {u} (Compound) treats {v} (Disease) testicular cancer
testicular cancer {u} (Disease) resembles {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bleomycin {u} (Compound) treats {v} (Disease) testicular cancer
testicular cancer {u} (Disease) resembles {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bleomycin {u} (Compound) binds {v} (Gene) LIG1
LIG1 {u} (Gene) is associated with {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Bleomycin {u} (Compound) binds {v} (Gene) LIG1
LIG1 {u} (Gene) is regulated by {v} (Gene) ABCC2
ABCC2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Bleomycin (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is treated by Carboplatin (Compound)
Bleomycin (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Carboplatin (Compound)
Bleomycin (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) resembles ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Carboplatin (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Bleomycin (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) resembles urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Carboplatin (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Bleomycin (Compound) binds LIG1 (Gene) and LIG1 (Gene) is associated with urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Carboplatin (Compound)
Bleomycin (Compound) binds LIG1 (Gene) and LIG1 (Gene) is regulated by ABCC2 (Gene) and ABCC2 (Gene) is bound by Carboplatin (Compound)